After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...